Helix BioPharma Announces Board Changes to Align with Strategic Goals

Helix BioPharma Corp. (TSX: HBP, OTC PINK: HBPCD, FRANKFURT: HBP0), a clinical-stage oncology company, has announced immediate changes to its Board of Directors. Janusz Grabski has resigned, and Thomas Mehrling, M.D., Ph.D., the company's CEO, has been appointed as a director. This appointment comes pursuant to the board nomination right granted to Laevoroc Immunology AG in connection with Helix’s 2025 acquisition of substantially all of the assets of Laevoroc Immunology AG and Laevoroc Chemotherapy AG.

The company stated that these changes are intended to ensure the board continues to meet Helix’s evolving governance and capital markets requirements, and has the composition and experience needed to support the company’s clinical development and broader corporate objectives. The Board thanked Mr. Grabski for his service and contributions.

Helix BioPharma is focused on developing therapies for underserved patient populations with difficult-to-treat cancers. Its pipeline is led by L-DOS47, a clinical-stage antibody-enzyme conjugate being developed as a combination therapy for non-small cell lung cancer (NSCLC). Additional candidates include LEUMUNA™, a pre-IND oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, a pre-IND gemcitabine prodrug for advanced solid tumors.

These governance changes occur as the company advances its clinical programs. The addition of Dr. Mehrling, who has extensive experience in oncology drug development, is expected to provide strategic guidance as Helix progresses its pipeline. The board’s composition is crucial for ensuring effective oversight and strategic direction, especially for a clinical-stage biotech navigating the complexities of drug development and capital markets.

The resignation of Mr. Grabski and the appointment of Dr. Mehrling reflect a deliberate effort to align the board with the company's current phase of growth and its focus on executing its clinical strategy. For investors and stakeholders, these changes signal a commitment to maintaining strong governance practices while pursuing the company's mission to bring innovative cancer therapies to patients in need.

Helix BioPharma’s common shares are listed on the Toronto Stock Exchange (TSX: HBP), quoted on the OTC Pink Market (HBPCD), and listed on the Frankfurt Stock Exchange (FWB: HBP0). More information about the company and its pipeline can be found at https://www.helixbiopharma.com/.